Results

1–10 of 15 results for Arshad M. Khanani

Faricimab in Neovascular Age-Related Macular Degeneration: Year 2 Efficacy, Safety, and Durability Results From the Phase 3 TENAYA and LUCERNE Trials
Arshad M. Khanani, MD, MA, FASRS
Annual Meeting Talks
2022
GATHER2 Phase 3 Efficacy Results and GATHER2 Phase 3 Safety Results
Jeffrey S. Heier, MD
Arshad M. Khanani, MD, MA, FASRS
Updates from the Field
2022
Analysis of Retinal Fluid and Vision Outcomes in the Archway Phase 3 Trial of the Port Delivery System With Ranibizumab (PDS) in Patients With nAMD
Arshad M. Khanani, MD, MA, FASRS
Annual Meeting Talks
2021
Faricimab in Neovascular Age-Related Macular Degeneration: Year 2 Efficacy, Safety, and Durability Results From the Phase 3 TENAYA and LUCERNE Trials
Arshad M. Khanani, MD, MA, FASRS
Updates from the Field
2022
RGX-314 for Neovascular AMD: Ongoing Phase I/IIa Results for Cohorts 1-5
Arshad M. Khanani, MD, MA, FASRS
Annual Meeting Talks
2020
Port Delivery System With Ranibizumab: Key Outcomes From the Ladder Phase 2 Trial That Supported Archway Phase 3 Study Design
Arshad M. Khanani, MD, MA, FASRS
Annual Meeting Talks
2019
Wieland-Khanani Port Delivery System
Mark R. Wieland, MD
Arshad M. Khanani, MD, MA, FASRS
Updates from the Field
Part 3: Implementing Clinical Trials in a Retina Practice: How to Get Started and Recruit Successfully (Part 3 of 3)
Arshad M. Khanani, MD, MA, FASRS
Carl J Danzig, MD
Charles C Wykoff, MD, PhD, FASRS
John D Pitcher, MD
Nikolas JS London, MD, FACS, FASRS
On Demand Cases, Courses, and Papers
2018
Part 2: Implementing Clinical Trials in a Retina Practice: How to Get Started and Recruit Successfully (Part 2 of 3)
Arshad M. Khanani, MD, MA, FASRS
Carl J Danzig, MD
On Demand Cases, Courses, and Papers
2018
Part 1: Implementing Clinical Trials in a Retina Practice: How to Get Started and Recruit Successfully (Part 1 of 3)
Arshad M. Khanani, MD, MA, FASRS
Charles C Wykoff, MD, PhD, FASRS
Carl J Danzig, MD
Nikolas JS London, MD, FACS, FASRS
On Demand Cases, Courses, and Papers
2018